Olivier Quenez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivier Quenez has a total of 952 co-authors. Here are the top co-authors by number of shared publications:
- Gaël Nicolas
Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and Reference Center for Developmental Disorders, Rouen, France
12 shared publications Robert Olaso
Universite Paris-Saclay, CEA, Centre National de Recherche en Genomique Humaine (CNRGH), 91057, Evry, France
8 shared publicationsAnne Boland
Universite Paris-Saclay, CEA, Centre National de Recherche en Genomique Humaine (CNRGH), 91057, Evry, France
7 shared publicationsAnne-Claire Richard
Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000, Rouen, France
7 shared publications- Alfredo Ramirez
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
6 shared publications Camille Charbonnier
Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Biostatistics and CNRMAJ, F-76000 Rouen, France
6 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5879-5888
Assessing the de novo paradigm in sporadic early-onset Alzheimer disease trios
The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown. To assess the de novo mutation (DNM) hypothesis, we performed a nationwide recruitment of 37 novel sEOAD patients-unaffected parents trios. After assessing known monogenic genes, we performed trio-based exome sequencing and jointly analyzed novel trios with 12 previously reported ones. Of these, we selected 16 trios for genome sequencing. We identified three patients with a pathogenic DNM in APP or PSEN1. Then, from the 46 remaining trios, we identified 38 non-synonymous coding DNM and 4 de novo copy number variants (CNVs) in exome data. Four DNM (2 novel, in SPHK2 and DDR1) and bi-allelic inherited variants in two genes affected Alzheimer disease-related genes. No significant burden of rare coding variants in exome/genome data from 5643 EOAD cases and 16097 controls was identified using nested windows centered on each DNM position, at the transcript level. From genome data, one non-coding DNM was predicted to affect splicing in an AD-associated gene, PINX1. Overall, 48% probands carried ≥1 inherited risk factor with odds ratio (OR) > 1.5 and GWAS-defined Genetic Risk Scores (GRS) distribution was more consistent with random distribution than enrichment in higher scores in probands. We confirm that DNMs in known monogenic genes explain sEOAD in a minority of cases, while candidate DNMs in other genes might account for a small proportion of additional cases. The majority of sEOAD patients may have a complex etiology including multiple inherited variants, however, GRS might not explain most of its genetic component.
- 29 May 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5879-5888
Open AccessAssessing the de novo paradigm in sporadic early-onset Alzheimer disease trios
The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown. To assess the de novo mutation (DNM) hypothesis, we performed a nationwide recruitment of 37 novel sEOAD patients-unaffected parents trios. After assessing known monogenic genes, we performed trio-based exome sequencing and jointly analyzed novel trios with 12 previously reported ones. Of these, we selected 16 trios for genome sequencing. We identified three patients with a pathogenic DNM in APP or PSEN1. Then, from the 46 remaining trios, we identified 38 non-synonymous coding DNM and 4 de novo copy number variants (CNVs) in exome data. Four DNM (2 novel, in SPHK2 and DDR1) and bi-allelic inherited variants in two genes affected Alzheimer disease-related genes. No significant burden of rare coding variants in exome/genome data from 5643 EOAD cases and 16097 controls was identified using nested windows centered on each DNM position, at the transcript level. From genome data, one non-coding DNM was predicted to affect splicing in an AD-associated gene, PINX1. Overall, 48% probands carried ≥1 inherited risk factor with odds ratio (OR) > 1.5 and GWAS-defined Genetic Risk Scores (GRS) distribution was more consistent with random distribution than enrichment in higher scores in probands. We confirm that DNMs in known monogenic genes explain sEOAD in a minority of cases, while candidate DNMs in other genes might account for a small proportion of additional cases. The majority of sEOAD patients may have a complex etiology including multiple inherited variants, however, GRS might not explain most of its genetic component.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Optimisation de la détection et de l'interpretation des variations génomiques issues de données d'exomes pour les études cas-contrôles
Au cours des 20 dernières années, l'évolution des nouvelles technologies a révélé la grande variabilitéde notre génome depuis la simple substitution jusqu'aux réarrangements chromosomiques. Lestechnologies de séquençage à haut débit ont particulièrement amélioré l’identification etl’interprétation des variations de petite taille tout en offrant l’opportunité d’explorer les variations destructure avec une résolution supérieure à celle disponible grâce aux analyses pangénomiques surpuces. Néanmoins, l’identification des variations de structure, et plus particulièrement des variationsdu nombre de copies (CNV) à partir de données de séquençage par capture, a été sous exploitée etpeu évaluée. Notre objectif principal était de mettre en place un pipeline bioinformatique basé sur laprofondeur de lecture pour l’identification des CNV, puis de l’appliquer à une études cas-témoinsd’exome dans le cadre de la recherche sur la maladie d’Alzheimer.La maladie d’Alzheimer (MA) est la maladie neurodégénérative la plus fréquente. Les facteursgénétiques individuels jouent un rôle important dans son déterminisme et de multiples facteurs derisque ont été identifiés, essentiellement des substitutions et petites insertions/délétions. Pourtant,des variations de structure ont déjà été identifiées dans des formes monogéniques de MA, comme lesduplications complètes du gène APP. Les CNV restent très peu étudiés dans la MA et nous avonssouhaité appliquer une approche cas-témoins à partir de données massives d’exomes pour détecterdes CNV contribuant au risque de MA.Dans un premier temps, nous avons établi une stratégie d'analyse basée sur le logiciel CANOES afin dedétecter les CNV à partir de données de NGS issues d’une capture (panel, exomes). Cette approche aété validée à travers deux grands jeux de données de panels et d’exomes comparés à des techniquesindépendantes. Dans le premier jeu de données (panels), la sensibilité et la spécificité étaient de 100%et nous obtenons une sensibilité de 87,25 % et une valeur prédictive positive de 88,5% sur la détectionde CNV sur les données de séquençage d'exomes.Par la suite, nous avons appliqué cette approche aux données d’exomes issues des consortium ADES(Alzheimer Disease Exome Sequencing) et ADSP (Alzheimer Disease Sequencing Project), regroupant,après un contrôle qualité extensif développé dans le cadre de ces travaux, 22 094 individus répartisentre 4077 formes précoces de MA, 8458 formes tardives et 9559 témoins. Nous avons mis au pointdes analyses au niveau des transcrits et appliqué une méthode statistique basée sur les dosagesappliquée aux formes précoces et aux témoins. Nous avons pu identifier plusieurs potentiels nouveauxfacteurs de risque dont la région du chr22q11.21, déjà impliquée dans les troubles duneurodéveloppement (p=3,8x10-4). De plus, nous avons identifié des délétions très rares dans lesgènes ABCA1 et ABCA7 dont les variations perte de fonction sont connues comme facteurs de risquede MA depuis peu, et nous avons réalisé une analyse conjointe des délétions et des variations pertede fonction de petite taille.En conclusion, nous avons montré que la détection de CNV issus de données d’exome est fiable et nousen avons mesuré les performances et les limites avant de les appliquer à un grand jeu de données afind’identifier de nouveaux mécanismes contribuant au développement de la maladie d’Alzheimer.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Optimisation de la détection et de l'interpretation des variations génomiques issues de données d'exomes pour les études cas-contrôles
Au cours des 20 dernières années, l'évolution des nouvelles technologies a révélé la grande variabilitéde notre génome depuis la simple substitution jusqu'aux réarrangements chromosomiques. Lestechnologies de séquençage à haut débit ont particulièrement amélioré l’identification etl’interprétation des variations de petite taille tout en offrant l’opportunité d’explorer les variations destructure avec une résolution supérieure à celle disponible grâce aux analyses pangénomiques surpuces. Néanmoins, l’identification des variations de structure, et plus particulièrement des variationsdu nombre de copies (CNV) à partir de données de séquençage par capture, a été sous exploitée etpeu évaluée. Notre objectif principal était de mettre en place un pipeline bioinformatique basé sur laprofondeur de lecture pour l’identification des CNV, puis de l’appliquer à une études cas-témoinsd’exome dans le cadre de la recherche sur la maladie d’Alzheimer.La maladie d’Alzheimer (MA) est la maladie neurodégénérative la plus fréquente. Les facteursgénétiques individuels jouent un rôle important dans son déterminisme et de multiples facteurs derisque ont été identifiés, essentiellement des substitutions et petites insertions/délétions. Pourtant,des variations de structure ont déjà été identifiées dans des formes monogéniques de MA, comme lesduplications complètes du gène APP. Les CNV restent très peu étudiés dans la MA et nous avonssouhaité appliquer une approche cas-témoins à partir de données massives d’exomes pour détecterdes CNV contribuant au risque de MA.Dans un premier temps, nous avons établi une stratégie d'analyse basée sur le logiciel CANOES afin dedétecter les CNV à partir de données de NGS issues d’une capture (panel, exomes). Cette approche aété validée à travers deux grands jeux de données de panels et d’exomes comparés à des techniquesindépendantes. Dans le premier jeu de données (panels), la sensibilité et la spécificité étaient de 100%et nous obtenons une sensibilité de 87,25 % et une valeur prédictive positive de 88,5% sur la détectionde CNV sur les données de séquençage d'exomes.Par la suite, nous avons appliqué cette approche aux données d’exomes issues des consortium ADES(Alzheimer Disease Exome Sequencing) et ADSP (Alzheimer Disease Sequencing Project), regroupant,après un contrôle qualité extensif développé dans le cadre de ces travaux, 22 094 individus répartisentre 4077 formes précoces de MA, 8458 formes tardives et 9559 témoins. Nous avons mis au pointdes analyses au niveau des transcrits et appliqué une méthode statistique basée sur les dosagesappliquée aux formes précoces et aux témoins. Nous avons pu identifier plusieurs potentiels nouveauxfacteurs de risque dont la région du chr22q11.21, déjà impliquée dans les troubles duneurodéveloppement (p=3,8x10-4). De plus, nous avons identifié des délétions très rares dans lesgènes ABCA1 et ABCA7 dont les variations perte de fonction sont connues comme facteurs de risquede MA depuis peu, et nous avons réalisé une analyse conjointe des délétions et des variations pertede fonction de petite taille.En conclusion, nous avons montré que la détection de CNV issus de données d’exome est fiable et nousen avons mesuré les performances et les limites avant de les appliquer à un grand jeu de données afind’identifier de nouveaux mécanismes contribuant au développement de la maladie d’Alzheimer.
- Open Access
Exome analysis of 22,319 individuals links extremely rare CNVs and 22q11.21 dosage to Alzheimer’s risk
Copy number variants (CNVs), defined as deletions or duplications of genomic segments >100 bp, are major contributors to human disease, yet their role in non-monogenic Alzheimer disease (AD) remains poorly characterized. We analyzed rare CNVs from 22,319 exomes, including 4,150 early-onset AD (EOAD), 8,519 late-onset AD and 9,650 unaffected controls. EOAD cases showed increased burdens of rare CNVs, particularly rare deletions within AD-related genes. Loss-of-function analyses implicated deletions in ABCA1 and ABCA7 and identified CTSB as a candidate locus . Exome-wide gene-level dosage analysis highlighted 18 genes across five loci , including chr22q11.21, where deletions were restricted to EOAD and duplications enriched in controls. Replication in 33,992 cases and 362,305 controls confirmed AD-risk reduction in 22q11.21 duplication carriers (mega-analysis dosage OR(SCARF2)=0.34, p=5.52×10 -7 ). SCARF2 overexpression increased amyloid-β uptake in vitro , supporting a functional link. These findings highlight CNVs as contributors to AD risk and identify 22q11.21 dosage as a strong genetic determinant.
Open AccessExome analysis of 22,319 individuals links extremely rare CNVs and 22q11.21 dosage to Alzheimer’s risk
Copy number variants (CNVs), defined as deletions or duplications of genomic segments >100 bp, are major contributors to human disease, yet their role in non-monogenic Alzheimer disease (AD) remains poorly characterized. We analyzed rare CNVs from 22,319 exomes, including 4,150 early-onset AD (EOAD), 8,519 late-onset AD and 9,650 unaffected controls. EOAD cases showed increased burdens of rare CNVs, particularly rare deletions within AD-related genes. Loss-of-function analyses implicated deletions in ABCA1 and ABCA7 and identified CTSB as a candidate locus . Exome-wide gene-level dosage analysis highlighted 18 genes across five loci , including chr22q11.21, where deletions were restricted to EOAD and duplications enriched in controls. Replication in 33,992 cases and 362,305 controls confirmed AD-risk reduction in 22q11.21 duplication carriers (mega-analysis dosage OR(SCARF2)=0.34, p=5.52×10 -7 ). SCARF2 overexpression increased amyloid-β uptake in vitro , supporting a functional link. These findings highlight CNVs as contributors to AD risk and identify 22q11.21 dosage as a strong genetic determinant.
- Top Cited PapersOpen Access
- 13 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Biallelic NAA60 variants with impaired N-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications
Primary familial brain calcification (PFBC) is characterized by calcium deposition in the brain, causing progressive movement disorders, psychiatric symptoms, and cognitive decline. PFBC is a heterogeneous disorder currently linked to variants in six different genes, but most patients remain genetically undiagnosed. Here, we identify biallelic NAA60 variants in ten individuals from seven families with autosomal recessive PFBC. The NAA60 variants lead to loss-of-function with lack of protein N-terminal (Nt)-acetylation activity. We show that the phosphate importer SLC20A2 is a substrate of NAA60 in vitro. In cells, loss of NAA60 caused reduced surface levels of SLC20A2 and a reduction in extracellular phosphate uptake. This study establishes NAA60 as a causal gene for PFBC, provides a possible biochemical explanation of its disease-causing mechanisms and underscores NAA60-mediated Nt-acetylation of transmembrane proteins as a fundamental process for healthy neurobiological functioning.
- 13 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Top Cited PapersOpen AccessBiallelic NAA60 variants with impaired N-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications
Primary familial brain calcification (PFBC) is characterized by calcium deposition in the brain, causing progressive movement disorders, psychiatric symptoms, and cognitive decline. PFBC is a heterogeneous disorder currently linked to variants in six different genes, but most patients remain genetically undiagnosed. Here, we identify biallelic NAA60 variants in ten individuals from seven families with autosomal recessive PFBC. The NAA60 variants lead to loss-of-function with lack of protein N-terminal (Nt)-acetylation activity. We show that the phosphate importer SLC20A2 is a substrate of NAA60 in vitro. In cells, loss of NAA60 caused reduced surface levels of SLC20A2 and a reduction in extracellular phosphate uptake. This study establishes NAA60 as a causal gene for PFBC, provides a possible biochemical explanation of its disease-causing mechanisms and underscores NAA60-mediated Nt-acetylation of transmembrane proteins as a fundamental process for healthy neurobiological functioning.
- 4 March 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (7) , 779-785
Upstream open reading frame-introducing variants in patients with primary familial brain calcification
More than 50% of patients with primary familial brain calcification (PFBC), a rare neurological disorder, remain genetically unexplained. While some causative genes are yet to be identified, variants in non-coding regions of known genes may represent a source of missed diagnoses. We hypothesized that 5ʹ-Untranslated Region (UTR) variants introducing an AUG codon may initiate mRNA translation and result in a loss of function in some of the PFBC genes. After reannotation of exome sequencing data of 113 unrelated PFBC probands, we identified two upstream AUG-introducing variants in the 5’UTR of PDGFB. One, NM_002608.4:c.-373C>G, segregated with PFBC in the family. It was predicted to create an upstream open reading frame (ORF). The other one, NM_002608.4:c.-318C>T, was found in a simplex case. It was predicted to result in an ORF overlapping the natural ORF with a frameshift. In a GFP reporter assay, both variants were associated with a dramatic decrease in GFP levels, and, after restoring the reading frame with the GFP sequence, the c.-318C>T variant was associated with a strong initiation of translation as measured by western blotting. Overall, we found upstream AUG-introducing variants in the 5’UTR of PDGFB in 2/113 (1.7%) undiagnosed PFBC cases. Such variants thus represent a source of putative pathogenic variants.
- 4 March 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (7) , 779-785
Upstream open reading frame-introducing variants in patients with primary familial brain calcification
More than 50% of patients with primary familial brain calcification (PFBC), a rare neurological disorder, remain genetically unexplained. While some causative genes are yet to be identified, variants in non-coding regions of known genes may represent a source of missed diagnoses. We hypothesized that 5ʹ-Untranslated Region (UTR) variants introducing an AUG codon may initiate mRNA translation and result in a loss of function in some of the PFBC genes. After reannotation of exome sequencing data of 113 unrelated PFBC probands, we identified two upstream AUG-introducing variants in the 5’UTR of PDGFB. One, NM_002608.4:c.-373C>G, segregated with PFBC in the family. It was predicted to create an upstream open reading frame (ORF). The other one, NM_002608.4:c.-318C>T, was found in a simplex case. It was predicted to result in an ORF overlapping the natural ORF with a frameshift. In a GFP reporter assay, both variants were associated with a dramatic decrease in GFP levels, and, after restoring the reading frame with the GFP sequence, the c.-318C>T variant was associated with a strong initiation of translation as measured by western blotting. Overall, we found upstream AUG-introducing variants in the 5’UTR of PDGFB in 2/113 (1.7%) undiagnosed PFBC cases. Such variants thus represent a source of putative pathogenic variants.
- Open Access
- 9 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-2
Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
- 9 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-2
Open AccessAuthor Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
- Top Cited PapersOpen Access
- 21 November 2022
- Published by Springer Nature in Nature Genetics
- Vol. 54 (12) , 1786-1794
Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease
Alzheimer’s disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70%1. The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants2. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individuals—16,036 AD cases and 16,522 controls. Next to variants inTREM2,SORL1andABCA7, we observed a significant association of rare, predicted damaging variants inATP8B4andABCA1with AD risk, and a suggestive signal inADAM10. Additionally, the rare-variant burden inRIN3, CLU, ZCWPW1andACEhighlighted these genes as potential drivers of respective AD-genome-wide association study loci. Variants associated with the strongest effect on AD risk, in particular loss-of-function variants, are enriched in early-onset AD cases. Our results provide additional evidence for a major role for amyloid-β precursor protein processing, amyloid-β aggregation, lipid metabolism and microglial function in AD.
- 21 November 2022
- Published by Springer Nature in Nature Genetics
- Vol. 54 (12) , 1786-1794
Top Cited PapersOpen AccessExome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease
Alzheimer’s disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70%1. The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants2. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individuals—16,036 AD cases and 16,522 controls. Next to variants inTREM2,SORL1andABCA7, we observed a significant association of rare, predicted damaging variants inATP8B4andABCA1with AD risk, and a suggestive signal inADAM10. Additionally, the rare-variant burden inRIN3, CLU, ZCWPW1andACEhighlighted these genes as potential drivers of respective AD-genome-wide association study loci. Variants associated with the strongest effect on AD risk, in particular loss-of-function variants, are enriched in early-onset AD cases. Our results provide additional evidence for a major role for amyloid-β precursor protein processing, amyloid-β aggregation, lipid metabolism and microglial function in AD.
- Open Access
- 20 November 2022
- Published by Wiley in Human Mutation
- Vol. 43 (12) , 2308-2323
SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing
Modeling splicing is essential for tackling the challenge of variant interpretation as each nucleotide variation can be pathogenic by affecting pre-mRNA splicing via disruption/creation of splicing motifs such as 5'/3' splice sites, branch sites, or splicing regulatory elements. Unfortunately, most in silico tools focus on a specific type of splicing motif, which is why we developed the Splicing Prediction Pipeline (SPiP) to perform, in one single bioinformatic analysis based on a machine learning approach, a comprehensive assessment of the variant effect on different splicing motifs. We gathered a curated set of 4616 variants scattered all along the sequence of 227 genes, with their corresponding splicing studies. The Bayesian analysis provided us with the number of control variants, that is, variants without impact on splicing, to mimic the deluge of variants from high-throughput sequencing data. Results show that SPiP can deal with the diversity of splicing alterations, with 83.13% sensitivity and 99% specificity to detect spliceogenic variants. Overall performance as measured by area under the receiving operator curve was 0.986, better than SpliceAI and SQUIRLS (0.965 and 0.766) for the same data set. SPiP lends itself to a unique suite for comprehensive prediction of spliceogenicity in the genomic medicine era. SPiP is available at: https://sourceforge.net/projects/splicing-prediction-pipeline/.
- 20 November 2022
- Published by Wiley in Human Mutation
- Vol. 43 (12) , 2308-2323
Open AccessSPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing
Modeling splicing is essential for tackling the challenge of variant interpretation as each nucleotide variation can be pathogenic by affecting pre-mRNA splicing via disruption/creation of splicing motifs such as 5'/3' splice sites, branch sites, or splicing regulatory elements. Unfortunately, most in silico tools focus on a specific type of splicing motif, which is why we developed the Splicing Prediction Pipeline (SPiP) to perform, in one single bioinformatic analysis based on a machine learning approach, a comprehensive assessment of the variant effect on different splicing motifs. We gathered a curated set of 4616 variants scattered all along the sequence of 227 genes, with their corresponding splicing studies. The Bayesian analysis provided us with the number of control variants, that is, variants without impact on splicing, to mimic the deluge of variants from high-throughput sequencing data. Results show that SPiP can deal with the diversity of splicing alterations, with 83.13% sensitivity and 99% specificity to detect spliceogenic variants. Overall performance as measured by area under the receiving operator curve was 0.986, better than SpliceAI and SQUIRLS (0.965 and 0.766) for the same data set. SPiP lends itself to a unique suite for comprehensive prediction of spliceogenicity in the genomic medicine era. SPiP is available at: https://sourceforge.net/projects/splicing-prediction-pipeline/.
- 23 July 2022
- Published by Wiley in Human Mutation
- Vol. 43 (12) , 1882-1897
Deep intronic NIPBL de novo mutations and differential diagnoses revealed by whole genome and RNA sequencing in Cornelia de Lange syndrome patients
Cornelia de Lange syndrome (CdLS; MIM# 122470) is a rare developmental disorder. Pathogenic variants in 5 genes explain approximately 50% cases, leaving the other 50% unsolved. We performed whole genome sequencing (WGS) ± RNA sequencing (RNA-seq) in 5 unsolved trios fulfilling the following criteria: (i) clinical diagnosis of classic CdLS, (ii) negative gene panel sequencing from blood and saliva-isolated DNA, (iii) unaffected parents' DNA samples available and (iv) proband's blood-isolated RNA available. A pathogenic de novo mutation (DNM) was observed in a CdLS differential diagnosis gene in 3/5 patients, namely POU3F3, SPEN, and TAF1. In the other two, we identified two distinct deep intronic DNM in NIPBL predicted to create a novel splice site. RT-PCRs and RNA-Seq showed aberrant transcripts leading to the creation of a novel frameshift exon. Our findings suggest the relevance of WGS in unsolved suspected CdLS cases and that deep intronic variants may account for a proportion of them.
- 23 July 2022
- Published by Wiley in Human Mutation
- Vol. 43 (12) , 1882-1897
Deep intronic NIPBL de novo mutations and differential diagnoses revealed by whole genome and RNA sequencing in Cornelia de Lange syndrome patients
Cornelia de Lange syndrome (CdLS; MIM# 122470) is a rare developmental disorder. Pathogenic variants in 5 genes explain approximately 50% cases, leaving the other 50% unsolved. We performed whole genome sequencing (WGS) ± RNA sequencing (RNA-seq) in 5 unsolved trios fulfilling the following criteria: (i) clinical diagnosis of classic CdLS, (ii) negative gene panel sequencing from blood and saliva-isolated DNA, (iii) unaffected parents' DNA samples available and (iv) proband's blood-isolated RNA available. A pathogenic de novo mutation (DNM) was observed in a CdLS differential diagnosis gene in 3/5 patients, namely POU3F3, SPEN, and TAF1. In the other two, we identified two distinct deep intronic DNM in NIPBL predicted to create a novel splice site. RT-PCRs and RNA-Seq showed aberrant transcripts leading to the creation of a novel frameshift exon. Our findings suggest the relevance of WGS in unsolved suspected CdLS cases and that deep intronic variants may account for a proportion of them.
- 17 May 2022
- Published by Wiley in Human Mutation
- Vol. 43 (9) , 1239-1248
uORF‐introducing variants in the 5′UTR of the NIPBL gene as a cause of Cornelia de Lange syndrome
Cornelia de Lange syndrome (CdLS) is a clinically-recognizable rare developmental disorder. About 70% of patients carry a missense or loss-of-function pathogenic variant in the NIPBL gene. We hypothesized that some variants in the 5'-untranslated region (UTR) of NIPBL may create an upstream open reading frame (uORF), putatively leading to a loss of function. We searched for NIPBL 5'-UTR variants potentially introducing uORF by (i) reannotating NGS data of 102 unsolved CdLS patients and (ii) literature and variant databases search. We set up a green fluorescent protein (GFP) reporter assay and studied NIPBL expression in a lymphoblastoid cell line (LCL). We identified two variants introducing a novel ATG codon sequence in the 5'-UTR of NIPBL, both predicted to introduce uORF: a novel c.-457_-456delinsAT de novo mutation in a 15-year-old male with classic CdLS, and a c.-94C>T variant in a published family. Our reporter assay showed a significant decrease of GFP levels in both mutant contexts, with similar levels of messenger RNA (mRNA) as compared to wt constructs. Assessment of LCL of one patient showed consistent results with decreased NIPBL protein and unchanged mRNA levels. 5'-UTR uORF-introducing NIPBL variants may represent a rare source of pathogenic variants in unsolved CdLS patients.
- 17 May 2022
- Published by Wiley in Human Mutation
- Vol. 43 (9) , 1239-1248
uORF‐introducing variants in the 5′UTR of the NIPBL gene as a cause of Cornelia de Lange syndrome
Cornelia de Lange syndrome (CdLS) is a clinically-recognizable rare developmental disorder. About 70% of patients carry a missense or loss-of-function pathogenic variant in the NIPBL gene. We hypothesized that some variants in the 5'-untranslated region (UTR) of NIPBL may create an upstream open reading frame (uORF), putatively leading to a loss of function. We searched for NIPBL 5'-UTR variants potentially introducing uORF by (i) reannotating NGS data of 102 unsolved CdLS patients and (ii) literature and variant databases search. We set up a green fluorescent protein (GFP) reporter assay and studied NIPBL expression in a lymphoblastoid cell line (LCL). We identified two variants introducing a novel ATG codon sequence in the 5'-UTR of NIPBL, both predicted to introduce uORF: a novel c.-457_-456delinsAT de novo mutation in a 15-year-old male with classic CdLS, and a c.-94C>T variant in a published family. Our reporter assay showed a significant decrease of GFP levels in both mutant contexts, with similar levels of messenger RNA (mRNA) as compared to wt constructs. Assessment of LCL of one patient showed consistent results with decreased NIPBL protein and unchanged mRNA levels. 5'-UTR uORF-introducing NIPBL variants may represent a rare source of pathogenic variants in unsolved CdLS patients.